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Module title: Current practice of internal medicine. 
1.Theme title: Management of patients with with infiltrative pulmo-
nary darkening. 
2.Theme specifications.  
3.Theme aims.  
4. The aim of this module is to provide the student with an oppor-
tunity to keeping patient in pulmonology clinic. 
5. Learning outcomes. 
 
Students should be able to describe and define:  
1.What is mean  by the term fever of unknown origin.  
2.The basic mechanisms of fever of unknown origin. 
3.The student should have an understanding of the pathophysiology 
of these diseases and be able to develop a comprehensive differential diag-
nosis.  The student will understand the appropriate diagnostic testing. The 
assessment, diagnosis and management the patient with fever of unknown 
origin. 
4.Risk Factors for Infective Endocarditis. 
5.Clinical manifestetions of Infective Endocarditis. 
6.Diagnosis of Infective Endocarditis. 
7.Treatment of Infective Endocarditis. 
8.Etiology and types of lung cncer. 
9.Clinical picture of lung cancer. 
10. Diagnosis and treatment of lung cancer. 
11.Etiology of tuberculosis. 
12.Types of tuberculosis. 
13. Clinical picture in tuberculosis. 
14. Diagnosis in tuberculosis. 
15. Treatment and prevention in tuberculosis. 
16. Complications of tuberculosis. 
17. Etiology and pathogenesis of sarcoidosis. 
18. Clinical picture and diagnosis of sarcoidosis. 
19. Treatment of sarcoidosis. 
20. Etiology and clinical picture of lung abcess. 
21.Diagnosis of lung abcess. 
22. Differential diagnosis between lung abcess,eisoinophilic granuloma 
and tuberculosis. 
23. Treatment of lung abcess. 
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TESTS AND ASSIGNMENTS FOR SELF-ASSESSMENT BASIC LEVEL  
OF KNOWLEDGE: MULTIPLE CHOICE QUESTIONS  
(CHOOSE THE CORRECT ANSWER/STATEMENT) 
 
1. A 25-year-old male non-smoker presents with progressive shortness 
of breath for the past 6 months. Physical examination shows decreased breath 
sounds over both lower lobes. Chest X-ray demonstrates emphysematous 
changes in both lower lobes. Past history is insignificant except for an episode 
of neonatal jaundice, which resolved promptly on the 4th day with photother-
apy. Routine blood count and differential counts are normal. Which of the fol-
lowing will help in establishing the diagnosis of his condition?  
A. Open lung biopsy. 
B. Estimating alpha -1 antitrypsin  
     levels. 
C. Video assisted lung biopsy. 
D. High resolution CT scan. 
E. ECG monitoring. 
 
2. Three weeks after visiting her grandmother dying from a respira-
tory tract infection, a healthy 5-year-old girl develops a fever along with 
wheezing. On physical examination her temperature is 37.9 C. Her lung 
fields are clear to auscultation but there are expiratory wheezes. A chest 
radiograph reveals a solitary 2 cm peripheral mid-lung nodule and marked 
hilar lymphadenopathy. Laboratory studies show Hgb 13.6 g/dL, platelet 
count 183,600/microliter, and WBC count 5480/microliter. These findings 
are most consistent with infection by which of the following organisms? 
A.  Mycobacterium tuberculosis. 
B.  Candida albicans. 
C.  Coccidioides immitis. 
D.  Aspergillus flavus. 
E.  Bacteroides fragilis. 
F. Streptococcus pneumoniae. 
G.  Respiratory syncytial virus. 
 
 
3. A 65-year-old man has had no major medical problems prior to the 
past year, when he noted increasing malaise along with an 8 kg weight loss. He 
is a non-smoker. He currently does not have fever, cough, dyspnea, or any 
respiratory difficulties. On physical examination, he has non-tender supraclavi-
cular lymphadenopathy. The lungs are clear to auscultation. A chest x-ray 
shows multiple solid nodules ranging from 1 to 3 cm scattered throughout all 
lung fields. No infiltrates or areas of consolidation are noted. Laboratory stud-
ies show Hgb 11.6 g/dL, Hct 34.7%, MCV 83 fL, and WBC count 
6280/microliter. Which of the following pathologic processes in his lungs is 
most likely to account for these findings? 
A.  Pulmonary infarctions. 
B.  Foreign body aspiration. 
C.  Metastatic carcinoma. 
D.  Nocardia asteroides infection. 
E.  Silicosis. 
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4. Оne fourth of patients with Upper respiratory tract infections cough is 
seen beyond 1 month of diseases due to if theses patient have. 
A. A hitory of asthma,allergy or 
     atopy(hay Fever). 
B. Immunocompromised (HIV). 
 
C. If the patient is on  
     immunosupressor medicines. 
D. A&B are correct. 
E. All of above are correct. 
 
5. Соugh is an early manifestation of many respiratory diseases and en-
dotracheal lesion what of listed conditions may support a diagnosis of lung 
cancer together with chronic cough. 
A. Hemoptysis,frequent upper respiratory tract infection,very high fever 
and chest pain. 
B. Chest pain,hemoptysis,low grade fever and night sweats. 
C. Localized weeze,decrease lung sounds on auscultation and high fever. 
D. Hemoptysis,frequent upper respiratory tract infections,clubbing 
of fingers and localized weeze low lung sound together with unexplained 
weight loss. 
E. Chest pain,hemoptysis,low grade fever and night sweats.low vocal 
feramitus and general weekness. 
 
6. Diffuse interstitial pneumonitis with interstitial edema, varying de-
grees of fibrosis, lymphoid cell infiltration, and alveolar-cell hyperplasia are 
pathological features typical of 
А. CMV. 
В. Influenza virus. 
 
С. RSV. 
D. Parainfluenza virus. 
 
Е. Paramyxovirus. 
 
 
7. A 50-year-old woman has lived in Oslo, Norway all her life and 
worked as a seamstress. She is a non-smoker, but she has had increasing 
shortness of breath, fever, weight loss, and night sweats for the past 4 
months. On physical examination her temperature is 37.6 C. There are fine 
rales auscultated in all lung fields. A chest radiograph reveals hilar lympha-
denopathy and a reticulonodular pattern of small densities in all lung fields. 
She demonstrates anergy by skin testing to mumps and Candidaantigens. A 
transbronchial biopsy is performed that microscopically shows numerous 
small pulmonary interstitial non-caseating granulomas. Which of the fol-
lowing is the most likely diagnosis? 
A.  Histoplasmosis. 
B. Adenocarcinoma. 
C.  Sarcoidosis. 
 
D.  Usual interstitial pneu 
      monitis. 
E.  Berylliosis. 
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8. A 55-year-old man with a 55 pack year history of smoking ciga-
rettes has recently experienced an episode of hemoptysis along with his 
usual cough. On physical examination there are no abnormal findings. He 
has a sputum cytology examination performed that on microscopic exami-
nation shows atypical cells with hyperchromatic nuclei and orange-pink 
cytoplasm. Labortory studies show a serum calcium of 11.3 mg/dL, with 
phosphorus 2.1 mg/dL. Which of the following chest radiographic findings 
is this man most likely to have? 
A.  Large hilar mass. 
B.  Pneumonia-like consolidation. 
C.  Peripheral nodule. 
D.  Carinal compression. 
E.  Left pleural thickening. 
 
 
9. A 40-year-old woman has had a high fever for a week, accompa-
nied by a cough productive of yellowish sputum. On physical examination 
her temperature is 38.2 C. There are diffuse rales in all lung fields. Her 
chest radiograph reveals patchy infiltrates in all lung fields, and there is a 
4 cm rounded area of consolidation in the left upper lobe that has an air-
fluid level. Examination of her sputum reveals numerous neutrophils. 
Which of the following infectious agents is most likely causing her pul-
monary disease? 
A.  Staphylococcus aureus. 
B.  Aspergillus niger. 
C.  Mycobacterium tuberculosis. 
D.  Mycoplasma pneumoniae. 
E.  Adenovirus. 
 
 
10. A 38-year-old previously healthy woman has had a worsening non-
productive cough for the past 4 days. On physical examination her temperature 
is 38.3 C. A chest radiograph shows patchy infiltrates and diffuse interstitial 
markings. Laboratory studies show a sputum gram stain with mixed flora. Her 
Hgb is 12.9 g/dL, platelet count 229,450/microliter, and WBC count 
5815/microliter. Her cold agglutinin titer is elevated. Following a course of 
erythromycin therapy, she improves, with no complications. Which of the fol-
lowing infectious agents is most likely to cause the pulmonary disease seen in 
this woman? 
A.  Nocardia asteroides. 
B.  Mycoplasma pneumoniae. 
C.  Mycobacterium kansasii. 
D.  Respiratory syncytial virus. 
E.  Chlamydia psittici. 
 
 
6. Indicative reading list. 
Kasper Dennis L., Braunwald Eugene, Fauci Anthony, Hauser Stephen, 
Longo Dan, Jameson J. Larry. Harrison’s Principles of Internal Medicine, 16th 
ed. McGraw-Hill Professional, 2004. 2800 p. 
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7. Indicative syllabus.  
 
LUNG CANCER 
Lung cancer  is a disease of uncontrolled cell growth in tissues of 
the lung. This growth may lead to metastasis, which is the invasion of adjacent 
tissue and infiltration beyond the lungs. The vast majority of primary lung 
cancers are carcinomas of the lung, derived from epithelial cells. Lung cancer  
the most common cause of cancer-related death in men and women, is respon-
sible for 1.3 million deaths worldwide annually. The most com-
mon symptoms are shortness of breath, coughing (including coughing up 
blood), and weight loss. 
The main types of lung cancer are small cell lung carci-
noma and non-small cell lung carcinoma. This distinction is important, 
because the treatment varies; non-small cell lung carcinoma (NSCLC) is 
sometimes treated with surgery, while small cell lung carcinoma (SCLC) 
usually responds better to chemotherapy and radiation. The most common 
cause of lung cancer is long-term exposure to tobacco smoke. The occur-
rence of lung cancer in nonsmokers, who account for as many as 15% of 
cases, is often attributed to a combination of genetic factors, radon 
gas, asbestos, and air pollution including second hand smoke. 
Lung cancer may be seen on chest radiograph and computed tomogra-
phy (CT scan). The diagnosis is confirmed with a biopsy. This is usually per-
formed by bronchoscopy or CT-guided biopsy.  
Treatment and prognosis depend upon the histological type of cancer, 
the stage (degree of spread), and the patient's performance status. Possible 
treatments include surgery, chemotherapy, and radiotherapy. Survival varies, 
depending on stage, overall health, and other factors, but the overall five-
year survival rate for all persons diagnosed with lung cancer is 14%. 
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Symptoms. There are no symptoms associated with early stage lung 
cancer. The American Cancer Society lists the following symptoms associated 
with advanced stage lung cancer. A physician should be consulted if they per-
sist. It is important to note, however, that these symptoms may be caused by 
factors unrelated to cancer: 
 Persistent cough. 
 Sputum streaked with blood. 
 Chest pain. 
 Voice change. 
 Recurrent pneumonia or bronchitis. 
Detection. Despite ongoing investigation into screening technology, re-
search shows that lung cancer death rates have not improved. At the time they 
are diagnosed, the majority of lung cancers have progressed to an advanced 
state. Lung cancer screening is not currently routine practice. The disease is 
sometimes caught in its early stages by tests that are performed for other rea-
sons. The most common methods of lung cancer detection include: 
 chest x-ray; 
 chest CT (computer tomography) scan; 
 bronchoscopy (insertion of a tube into the bronchi), and; 
 sputum cytology (examination of cells in the phlegm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment 
As our focus is on the biology of 
the cancers and their treatments, we do not 
give detailed treatment guidelines. Instead, 
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we link to organizations in the U.S. 
that generate the treatment guidelines. 
The National Comprehensive Cancer Network (NCCN) lists the follow-
ing treatments for lung cancer: 
 Surgery 
 Radiation Therapy 
 Chemotherapy 
 
Chemotherapy. The term chemotherapy, or chemo, refers to a wide 
range of drugs used to treat cancer. These drugs usually work by killing divid-
ing cells. Since cancer cells have lost many of the regulatory functions present 
in normal cells, they will continue to attempt to divide when other cells do not. 
This trait makes cancer cells susceptible to a wide range of cellular poisons. 
The chemotherapy agents work to cause cell death in a variety of ways. 
Some of the drugs are naturally occurring compounds that have been identified 
in various plants and some are man-made chemicals. A few different types of 
chemotherapy drugs are briefly described below. For more information on a 
particular type of drug, choose from the list below. 
 Antimetabolites: Drugs that interfere with the formation of key 
bio-molecules within the cell including nucleotides, the building blocks of 
DNA. These drugs ultimately interfere with DNA replication and therefore 
cell division. 
 Genotoxic Drugs: Drugs that damage DNA. By causing DNA dam-
age, these agents interfere with DNA replication, and cell division. 
 Spindle Inhibitors: These agents prevent proper cell division by inter-
fering with the cytoskeletal components that enable one cell to divide into two. 
 Other Chemotherapy Agents: These agents inhibit cell division by 
mechanisms that are not covered in the three categories listed above. 
 Glossary of Chemotherapy Agents: An easy to use table of chemo-
therapy drugs including trade name, generic name, and type. With links to more 
information. 
Normal cells are more resistant to the drugs because they often stop di-
viding when conditions are not favorable. Not all normal dividing cells escape 
however, a fact that contributes to the toxicity of these drugs. Cell types that are 
normally rapidly dividing, such as those in the bone marrow and in the lining of 
the intestine, tend to be hardest hit. Death of the normal cells produces some of 
the common side-effects of chemotherapy. 
Combination therapy, as is used for small cell lung carcinoma, has some 
effect in treating metastatic carcinoids. However, the response rate is only ap-
proximately 50%. Adjuvant chemotherapy along with postoperative radiation has 
been advocated for atypical lesions associated with mediastinal nodal extension. 
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Radiation therapy. Carcinoid tumors are generally radioresistant. An-
ecdotal reports describe tumor responses in inoperable cases. Radiation therapy 
is recommended for postoperative management of incompletely resected atypi-
cal lesions and in the presence of mediastinal nodal involvement. Data support-
ing the efficacy of this treatment are lacking. 
Adenoid cystic tumors are radiosensitive and postoperative radiotherapy 
is of value. 
Surgical Care. 
Endoscopic resection: Bronchoscopic resection. This procedure is 
plagued by incomplete tumor removal, with frequent recurrence due to 
extraluminal tumor bulk, often with limited tumor visibility and accessibil-
ity via the bronchoscope. It also carries a high risk of hemorrhage. 
Bronchoscopic resection is warranted to alleviate bronchial obstruc-
tion in patients in whom thoracotomy is prohibitive. Additionally, occa-
sional preoperative use of this technique may allow assessment of the re-
versibility of distal parenchymal damage. Finally, the technique of argon-
beam electrocoagulation may be very useful for bronchoscopic control of 
bleeding prior to definitive resection. 
Endoscopic resection: Neodymium:Yttrium-aluminum-garnet laser.  
The Nd: YAG laser reduces the risk of hemorrhage-related complications by 
means of photocoagulation. It is not recommended as a primary mode of tumor 
removal. Rarely, the Nd: YAG laser is applicable to a polypoid, easily accessi-
ble lesion on a narrow, uninvolved stalk. 
Surgical resection. In the past, as many as 62% of patients with bron-
chial adenomas underwent lobectomy or pneumonectomy. They frequently had 
significant delays in their diagnosis and had complete obstruction of a bronchus 
with distal parenchymal destruction. Complete tumor removal, removal of all 
destroyed lung parenchyma, nodal dissection, and preservation of functional 
parenchyma are the goals of resectional therapy 
Surgical procedures overview. Preoperative endobronchial resection 
may be used as part of the preparation of the patient for surgical resection 
Bronchotomy/bronchial wedge resection. Polypoid tumors are 
accessible by bronchotomy and excision, including the involved bronchial 
wall. Bronchotomy ensures complete resection (as compared to endo-
scopic removal, which may not), and wedge resection may be appropriate 
for small lesions lacking atypia. These procedures may be accompanied 
by nodal sampling. 
Lobectomy with or without sleeve resection. This is the most com-
monly used technique because most tumors occur in or near the origin of lobar 
bronchi. Concomitant sleeve resection of the main stem is required if the orifice 
of the lobar bronchus or the adjacent main stem bronchus is involved. Bron-
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choplastic adjuncts may permit preservation of normal distal parenchyma and 
are preferred over pneumonectomy when possible 
Pneumonectomy. Pneumonectomy may be required if all lobes on the 
involved side are destroyed because of a proximal obstructing lesion 
Preoperative risk assessment. Preopertive testing is done to assist in 
risk assessment and to identify areas of concern that can be mitigated prior to 
surgical intervention. Tests and evaluations other than those listed below may 
be appropriate as suggested by history, physical examination, and laboratory 
testing findings, but all of the listed tests are not routinely required. 
History (focusing on factors known to affect operative risk) may include 
the following: 
 Chronic obstructive pulmonary disease. 
 Chronic renal failure.  
 Cor pulmonale.  
 Diabetes mellitus.  
 Myocardial infarction within 6 months or unstable ischemic disease.  
 Severe cardiac valvular disease.  
 Congestive heart failure. 
Sarcoidosis. Sarcoidosis is idiopathic, and the trigger antigen inciting 
granuloma formation is unknown. The prominent involvement of the pulmo-
nary system has raised the possibility of inciting airborne agents, but to date no 
infectious organism has been definitely linked. 
Primarily, the lymphoreticular system is affected with prominent cervi-
cal and mediastinal lymphadenopathy (eg, perihilar and peritracheal nodes) and 
also involvement of the smaller scattered lymphatic collections in solid organs 
(eg, spleen, liver) and lymphoid tissue surrounding glandular organs such as 
theparotid and lacrimal glands. 
Debate continues as to whether sarcoidosis results from a dysfunctional 
immune system or a secondary response to environmental antigens. Sarcoid 
granulomas may be seen in solid organs such as liver, kidney, and spleen. Neu-
rosarcoidosis results from nervous system involvement by sarcoid granulomas. 
The clinical features of neurosarcoidosis depend on the site of neuraxis 
involved. While neurosarcoidosis most commonly affects the central nervous 
system, a subset of patients demonstrate predominantly peripheral nervous 
system involvement. This may manifest as a myopathy and/or a peripheral 
neuropathy depending on the distribution of the granulomas. 
The true incidence of peripheral neuropathy in sarcoidosis is unknown, 
as a significant number of asymptomatic patients with sarcoidosis have sub-
clinical peripheral nerve involvement. 
Neuropathy occurs via 2 mechanisms. The tissue can be involved di-
rectly: in muscle, a slow and indolent myositis results, and in the nerve, a neu-
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ropathy results. Granulomas in the nerve are seen most often in the perineurium 
and the epineurium, with local effects leading to axonal damage. 
Some studies reveal sparing of the endoneurium, but others show 
prominent infiltration of the endoneurium, suggesting that all 3 nerve layers 
may be involved. Occasionally, myelin loss is prominent, with appearance of 
myelin ovoids. Whether the latter are due to compression from the granulomas, 
a result of regional toxic effects, or a result of specific targeting of the myelin 
sheath is unclear. 
Tajima suggested a predominance of helper T cells in the sarcoid 
granulomas. Inflammation of the vasa nervorum or the arterioles to the 
muscles can result in ischemic injury or severe vasculitic neuropathy. A 
significant increase of the HLA allele DQB 1 0602 has been reported in 
sarcoidosis patients with small fiber neuropathy and this allele has been 
associated with severe course of disease.   
Peripheral nerve injury from these mechanisms may result in a diffuse 
polyneuropathy, mononeuritis multiplex, focal mononeuropathies, or poly-
radiculopathy from involvement of spinal root sheaths. The spinal root sheaths 
are an extension of the pachymeninges and a tissue for which sarcoid granulo-
mas have a particular predilection.  
 
Differential Diagnoses 
 Acute Inflammatory Demyelinating Polyradicu-
loneuropathy 
Metabolic Neuropa-
thy 
Alcohol (Ethanol) Related Neuropathy Neuropathy of Lep-
rosy 
Cauda Equina and Conus Medullaris Syndromes Neurosarcoidosis 
HIV-1 Associated Acute/Chronic Inflammatory 
Demyelinating Polyneuropathy 
Neurosyphilis 
HIV-1 Associated Distal Painful Sensorimotor 
Polyneuropathy 
Peroneal Mononeu-
ropathy 
HIV-1 Associated Multiple Mononeuropathies Ulnar Neuropathy 
Lyme Disease  
Metabolic Myopathies  
Laboratory Studies. The diagnosis of peripheral neuropathy as a result of 
sarcoidosis is determined by establishing in the first instance the presence of a 
peripheral neuropathy; excluding the common causes of peripheral neuropathy, 
such as hyperglycemic states, deficiencies of vitamins, and presence of toxins 
such as heavy metals; and establishing a pathological diagnosis of noncaseating 
granulomas, in neural or extraneural sites. 
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 A complete blood (CBC) count with differential may show a variety of 
changes, as follows. 
 Normochromic normocytic anemia. 
 Megaloblastic changes. 
 Basophilic stippling. 
 Other dyshematopoietic states. 
 Lymphopenia. 
 Erythrocyte sedimentation rate (ESR) may be elevated in systemic sar-
coidosis. 
 Blood tests are needed to look at hyperglycemic states, which include 
fasting glucose and glycosylated hemoglobin. If these results are normal, then a 
2-hour oral glucose tolerance test is needed. 
 Serum B-12 level: If on the low side, this should be pursued by se-
rum homocysteine and methylmalonic acid levels (expected to be high in B-
12 deficiency). 
 Serum protein immune electrophoresis. 
 Angiotensin-converting enzyme (ACE) level is rarely elevated in iso-
lated neuropathy but may be elevated in systemic sarcoidosis. 
 Blood urea nitrogen (BUN), creatinine, and serum calcium should be 
checked to rule out long-standing metabolic derangements, which can result in 
neuropathy. Hypercalcemia is a known feature of systemic sarcoidosis, and 
abnormalities of renal functions may reflect a wider involvement of the primary 
disease process. 
 Liver function tests (eg, alanine aminotransferase, aspartate ami-
notransferase, bilirubin, alkaline phosphatase, gamma glutamyl transpepti-
dase), if abnormal, may reflect systemic involvement by either sarcoidosis 
or other diseases. 
Imaging Studies. 
Chest radiography. 
 Chest radiography often demonstrates perihilar lymphadenopathy or 
the interstitial lung disease of sarcoidosis. These abnormalities also may sug-
gest lymphoma or other systemic diseases. 
 Whole-body gallium scan or fluorodeoxyglucose positron emission 
tomographic (FDG-PET) scan may reveal otherwise occult/subclinical areas 
of involvement, demonstrate the extent of disease, and suggest possible 
biopsy sites. 
 Magnetic resonance imaging (MRI) with gadolinium is helpful in 
identifying T2 enhancement of nerve roots, plexuses, and limb nerves. 
MR peripheral nerve imaging may occasionally show a diffusely 
enlarged nerve as a soft tissue mass. 
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 Imaging studies of specific regions or organ systems may be appropri-
ate if clinically indicated or if laboratory testing suggests involvement of that 
organ system. 
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Other Tests 
 Skin tests: Cutaneous anergy can be seen in systemic or active pulmo-
nary sarcoidosis. However, it almost never occurs in pure neurosarcoidosis. 
 Lumbar puncture 
 Cerebrospinal fluid (CSF) examination shows pleocytosis and elevated 
protein if the root sheaths or meninges are involved. 
 In these situations, glucose levels also may be reduced. 
 When the involvement is purely peripheral (eg, diffuse peripheral neu-
ropathy or myopathy), the CSF findings are normal. 
 Small fiber neuropathy may be evaluated by thermal threshold testing 
(TTT). On the other hand, sympathetic skin responses and cardiac autonomic 
testing (by Ewing test and123 I-MIBG myocardial scanning) have been reported 
to have limited diagnostic value for evaluation of small fiber neuropathy. 
 Electrophysiologic studies 
Nerve conduction studies (NCS) and electromyography (EMG) dem-
onstrate the presence of a diffuse, focal, or multifocal neuropathy or poly-
radiculopathy. 
 EMG often shows features of an axonal polyneuropathy. 
 Studies investigating the involvement of small diameter unmyelinated 
fibers have revealed a higher prevalence of small-fiber neuropathy than previ-
ously recognized. 
Medical Care 
 Several treatment regimens have been proposed. However, no defini-
tive treatment exists. 
 Corticosteroids remain the standard treatment, although response may 
be slow. Patients resistant to oral steroids may improve with pulsed intravenous 
methylprednisone. 
 Immunosuppressants such as cyclosporine, methotrexate, and cyclo-
phosphamide have been used with varying results. Almost all of the studies 
completed to date have involved treatment of CNS sarcoidosis as opposed to 
peripheral neuropathy. A case report of a biopsy-proven axonal sensorimotor 
polyneuropathy responding to intravenous immunoglobulin while unresponsive 
to steroid therapy is described. 
 There have been anecdotal reports of improvement with intravenous 
immunoglobulin therapy in patients who have failed conventional therapy. The 
response may be related to amelioration of vasculitic neuropathy. 
 Anecdotally, small fiber neuropathy has been reported to show im-
provement following treatment with infliximab. 
 Local radiation therapy may resolve nerve swelling. 
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Medications used in peripheral neuropathy in sarcoidosis are the same as 
those used for systemic sarcoidosis and neurosarcoidosis. Immunosuppressants 
are used to dampen or alter the inflammatory activity. Corticosteroids are pre-
ferred. Nonresponders may be tried on cyclosporine, azathioprine, and/or 
methotrexate. 
Immunosuppressants. Corticosteroids alter the immune response and 
may lead to resolution of the granulomas in sarcoidosis. 
Prednisone. Most commonly used oral corticosteroid, works by altering 
immune system and decreasing inflammatory reaction that is responsible for 
granuloma formation. Tuberculin skin test required prior to commencing high 
daily dose of steroids. Improvement has been reported in patients with sarcoid 
polyneuropathy who received methylprednisolone (1 g/wk for 8 wk) when oral 
prednisone failed. Disagreement exists about optimal treatment dose, but doses 
listed here are typical. 
Often, high dose required for period of 2-4 wk before tapering; taper 
may need to be continued for several months before discontinuing treatment 
altogether. 
Occasionally, patients respond to methylprednisolone pulses when high-
dose oral prednisone fails. 
Adult. Starting dose: 1-1.5 mg/kg/d PO; maintain this dose until clinical 
response seen; taper dose steadily over several months, titrating according to 
clinical response 
Pediatric. 1-1.5 mg/kg/d PO; if possible, taper dose more quickly in 
children because of adverse metabolic and growth retardation effects of steroids 
Cytotoxic drug/immunosuppressants. These agents suppress the auto-
immune response, which is responsible for granuloma formation. 
Cyclosporine. Used extensively in patients who have undergone trans-
plant. Beneficial effects in neurosarcoidosis have been reported, although most 
clinical scenarios have been central and not peripheral nervous system sarcoi-
dosis. Has been found to have benefit when used as adjunct to steroids in 6 
patients with CNS involvement of neurosarcoidosis. 
Adult. 3-6 mg/kg/d PO. 
Pediatric. Administer as in adults. 
Azathioprine. Cytostatic drug that has been used in numerous immune-
mediated diseases. Active component, 6-mercaptopurine, thought to have im-
mune-suppressing properties. 
Adult. 50 mg/d PO initial dose; increase by 50 mg/d weekly to desired 
dose 3-5 mg/kg PO usual dose for all age groups. 
Pediatric. Administer as in adults. 
Methotrexate. Antimetabolite used as immunosuppressant, often in 
rheumatoid arthritis, severe psoriasis, and certain neoplastic diseases. Its use for 
neurosarcoidosis has not been tested sufficiently. 
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Adult. Dosage varies depending on indication; one patient with CNS 
neurosarcoidosis has been described as benefiting from 25 mg/wk PO 
Starting dose varies from 25-30 mg/d PO; maintenance dose usually 7.5 mg/d 
Pediatric. Not established except for cancer therapy 
Lung abscess 
Lung abscess is necrosis of the pulmonary tissue and formation of cavi-
ties (more than 2 cm) containing necrotic debris or fluid caused by micro-
bial infection. 
This pus-filled cavity is often caused by aspiration, which may occur 
during altered consciousness. Alcoholism is the most common condition pre-
disposing to lung abscesses. 
Lung abscess is considered primary (60%) when it results from existing 
lung parenchymal process and is termed secondary when it complicates another 
process e.g. vascular emboli or follows rupture 
of extrapulmonary abscess into lung. 
Causes 
Conditions contributing to lung abscess 
 Aspiration of oropharyngeal or gastric secretion 
 Septic emboli 
 Necrotizing pneumonia 
 Vasculitis: Wegener granulomatosis 
 Necrotizing tumors: 8% to 18% are due to neoplasms across all age 
groups, higher in older people; primary squamous carcinoma of the lung is the 
commonest. 
Organisms. In the post-antibiotic era pattern of frequency is changing. 
In older studies anaerobes were found in up to 90% cases but they are much 
less frequent now. 
 Anaerobic bacteria: Peptostreptococcus, Bacteroides, Fusobacterium  species; 
 Microaerophilic streptococcus : Streptococcus milleri 
 Aerobic bacteria: Staphylococcus, Klebsiella, Haemophilus, Pseudomonas,  
 Nocardia, Escherichia coli, Streptococcus, Mycobacteria; 
 Fungi: Candida, Aspergillus 
 Parasites: Entamoeba histolytica, 
Symptoms. Onset of symptoms is often gradual, but in necrotizing 
staphylococcal or gram-negative bacillary pneumonias patients can be acutely 
ill. Cough, fever with shivering and night sweats are often present. Cough can 
be productive with foul smelling purulent sputum (≈70%) or less frequently 
with blood (i.e. hemoptysis in one third cases) Affected individuals may also 
complain of chest pain, shortness of breath, lethargy and other features of 
chronic illness. 
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Patients are generally cachectic at presentation. Finger clubbing is pre-
sent in one third of patients[. Dental decay is common especially in alcoholics 
and children. On examination of chest there will be features of consolidation 
such as localised dullness on percussion, bronchial breath sound etc. 
Diagnosing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chest X ray and other imaging studies. Abscess is often unilateral and 
single involving posterior segments of the upper lobes and the apical segments 
of the lower lobes as these areas are gravity dependent when lying down. Pres-
ence of air-fluid levels implies rupture into the bronchial tree or rarely growth 
of gas forming organism. 
Laboratory studies. Raised inflammatory markers (high ESR, CRP) are 
usual but not specific. Examination of sputum is important in any pulmonary 
infections and here often reveals mixed flora. Transtracheal of  (via broncho-
scopy) aspirates can also be cultured. Fibre optic bronchoscopy is often per-
formed to exclude obstructive lesion; it also helps in bronchial drainage of pus. 
Management. Broadspectrum antibiotic to cover mixed flora is the mainstay of 
treatment. Pulmonary physiotherapy and postural drainage are also important. Surgical 
procedures are required in selective patients for drainage or pulmonary resection. 
Antibiotic Therapy. Standard treatment of an anaerobic lung infection is 
clindamycin (600 mg IV q8h followed by 150-300 mg PO qid). This regimen has 
been shown to be superior over parenteral penicillin in published trials. Several 
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anaerobes may produce beta-lactamase (eg, various species of Bactero-
ides and Fusobacterium) and therefore develop resistance to penicillin. 
Although metronidazole is an effective drug against anaerobic bacteria, 
the experience with metronidazole in treating lung abscess has been rather 
disappointing because these infections are generally polymicrobial. A failure 
 Rate of 50% has been reported. 
 In hospitalized patients who have aspirated and developed a lung ab-
scess, antibiotic therapy should include coverage against S aure-
us and Enterobacter and Pseudomonas species. 
 Ampicillin plus sulbactam is well tolerated and as effective as clinda-
mycin with or without a cephalosporin in the treatment of aspiration pneumonia 
and lung abscess. 
 Moxifloxacin is clinically effective and as safe as ampicillin plus 
sulbactam in the treatment of aspiration pneumonia and lung abscess. 
Duration of therapy 
 Although the duration of therapy is not well established, most clini-
cians generally prescribe antibiotic therapy for 4-6 weeks. 
 Expert opinion suggests that antibiotic treatment should be continued 
until the chest radiograph has shown either the resolution of lung abscess or the 
presence of a small stable lesion. 
 The rationale for extended treatment maintains that risk of relapse ex-
ists with a shorter antibiotic regimen. 
Response to therapy 
 Patients with lung abscesses usually show clinical improvement, with 
improvement of fever, within 3-4 days after initiating the antibiotic therapy. 
Defervescence is expected in 7-10 days. Persistent fever beyond this time indi-
cates therapeutic failure, and these patients should undergo further diagnostic 
studies to determine the cause of failure. 
 Considerations in patients with poor response to antibiotic therapy in-
clude bronchial obstruction with a foreign body or neoplasm or infection with a 
resistant bacteria, mycobacteria, or fungi. 
 Large cavity size (ie, > 6 cm in diameter) usually requires prolonged ther-
apy. Because empyema with an air-fluid level could be mistaken for parenchymal 
abscess, a CT scan may be used to differentiate this process from lung abscess. 
 A nonbacterial cause of cavitary lung disease may be present, such as lung 
infarction, cavitating neoplasm, and vasculitis. The infection of a preexisting seques-
tration, cyst, or bulla may be the cause of delayed response to antibiotics. 
Surgical Care. Surgery is very rarely required for patients with uncom-
plicated lung abscesses. The usual indications for surgery are failure to respond 
to medical management, suspected neoplasm, or congenital lung malformation. 
The surgical procedure performed is either lobectomy or pneumonectomy. 
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When conventional therapy fails, either percutaneous catheter drainage 
or surgical resection is usually considered. Endoscopic lung abscess drainage is 
considered if an airway connection to the cavity can be demonstrated. Success 
of this treatment represents an additional option other than percutaneous cathe-
ter drainage or surgical resection. 
 
TUBERCULOSIS 
Tuberculosis or TB (short for tubercles bacillus) is a common and often 
deadly infectious disease caused by various strains ofmycobacteria, usu-
ally Mycobacterium tuberculosis in humans. Tuberculosis usually attacks 
the lungs but can also affect other parts of the body. It is spread through the air 
when people who have the disease cough, sneeze, or spit. Most infections in 
humans result in anasymptomatic, latent infection, and about one in ten latent 
infections eventually progresses to active disease which, if left untreated, kills 
more than 50% of its victims. 
The classic symptoms are a chronic cough with bloodtin-
ged sputum, fever, night sweats, and weight loss. Infection of other organs causes a 
wide range of symptoms. Diagnosis relies on radiology (commonly chest X-rays), 
a tuberculin skin test, blood tests, as well as microscopic examination 
and microbiological culture of bodily fluids. Treatment is difficult and requires 
long courses of multiple antibiotics. Contacts are also screened and treated if 
necessary. Antibiotic resistance is a growing problem in (extensively) multi-
drug-resistant tuberculosis. Prevention relies on screening programs 
and vaccination, usually with Bacillus Calmette-Guérin vaccine. 
One third of the world's population are thought to be infected with M. 
tuberculosis, and new infections occur at a rate of about one per second. The 
proportion of people who become sick with tuberculosis each year is stable or 
falling worldwide but, because of population growth, the absolute number of 
new cases is still increasing. In 2007 there were an estimated 13.7 million 
chronic active cases, 9.3 million new cases, and 1.8 million deaths, mostly 
in developing countries. In addition, more people in the developed world are 
contracting tuberculosis because their immune systems are compromised 
by immunosuppressive drugs, substance abuse, or AIDS. The distribution of 
tuberculosis is not uniform across the globe; about 80% of the population in 
many Asian and African countries test positive in tuberculin tests, while only 5-
10% of the US population test positive. 
Tuberculosis classification 
The current clinical classification system for tuberculosis (TB) is based 
on the pathogenesis of the disease. 
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Classification System for TB 
 
Class Type Description 
0 No TB exposure Not infected 
No history of exposure 
Negative reaction to tuberculin skin test 
1 TB exposure No evidence of infection 
History of exposure 
Negative reaction to tuberculin skin test 
Ghon complex 
2 TB infection No disease 
Positive reaction to tuberculin skin test 
Negative bacteriologic studies (if done) 
Fibrocaseous cavitary lesion (usually in 
upper lobe of lungs) 
3 TB, clinically active 
M. tuberculosis cultured (if done) 
Clinical, bacteriologic, or radiographic 
evidence of current disease 
4 TB Not clinically active 
History of episode(s) of TB 
or 
Abnormal but stable radiographic findings 
Positive reaction to the tuberculin skin test 
Negative bacteriologic studies (if done) 
and 
No clinical or radiographic evidence of 
current disease 
5 TB suspect 
Diagnosis pending 
TB disease should be ruled in or out 
within 3 months 
 
When the disease beco-
mes active, 75% of the cases 
are pulmonary TB, that is, TB in 
the lungs. Symptoms inclu-
de chest pain, coughing up 
blood, and a productive, pro-
longed cough for more than 
three weeks.  
Systemic symptomsiclu-
de fever, chills, night sweats, appetite 
loss, weight loss, pallor, and often a 
tendency to fatigue very easily.  
In the other 25% of active 
cases, the infection moves from the 
lungs, causing other kinds of TB, collectively denoted extrapulmonary tubercu-
losis. This occurs more commonly in immunosuppressed persons and young 
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children. Extrapulmonary infection sites include thepleura in tuberculosis pleu-
risy, the central nervous system in meningitis, the lymphatic sys-
tem in scrofula of the neck, the genitourinary system in urogenital tuberculosis, 
and bones and joints in Pott's disease of the spine. An especially serious form is 
disseminated TB, more commonly known as miliary tuberculosis. Extrapul-
monary TB may co-exist with pulmonary TB as well.  
 
Signs and symptoms 
History 
 Patients with miliary tuberculosis (TB) may experience progressive 
symptoms over days to weeks or occasionally over several months. Symptoms 
include the following: 
 Weakness, fatigue (90%) 
 Weight loss (80%) 
 Headache (10%) 
Physical 
 Signs of miliary TB include the following: 
 Subtle signs, such as low-grade fever (20%) 
 Fever (80%) 
 Cough (60%) 
 Generalized lymphadenopathy (40%) 
 Hepatomegaly (40%) 
 Splenomegaly (15%) 
 Pancreatitis (<5%) 
Multiorgan dysfunction, adrenal insufficiency 
 
Causes 
 Risk factors for miliary TB involve immunosuppression and include, 
but are not limited to, the following: 
 Cancer 
 Transplantation 
HIV infection 
 Malnutrition 
 Diabetes 
Silicosis 
 End-stage renal disease 
 Major surgical procedures - Occasionally may trigger dissemination 
 
 
 
 
 23 
Differential diagnoses 
 
Acute Respiratory Distress Syndrome Hyponatremia 
Addison Disease Influenza 
Alcoholism Lactic Acidosis 
Ascites Pneumocystis Carinii Pneumonia 
Blastomycosis Pneumonia, Bacterial 
Bone Marrow Failure Pneumonia, Community-Acquired 
Cardiac Tamponade Pneumonia, Fungal 
Disseminated Intravascular Coagulation Pneumonia, Viral 
Eosinophilic Pneumonia Sarcoidosis 
Epididymal Tuberculosis Silicosis 
Histoplasmosis  
Hypersensitivity Pneumonitis  
 
Other Problems to Be Considered 
Fungal infection 
Histiocytosis X (Langerhans cell histiocytosis) 
HIV-related pulmonary opportunistic infections 
Lymphangitic spread of cancer (eg, thyroid carcinoma, malignant melanoma) 
Measles 
Pancreatic abscess 
Pulmonary alveolar microlithiasis 
Talc granulomatosis 
Laboratory Studies 
 Chemistry 
 Hyponatremia: A decrease in sodium levels may correlate with disease 
severity. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 
or hypoadrenalism may complicate tuberculosis (TB). 
 Alkaline phosphatase levels are elevated in approximately 30% of cases. 
 Elevated levels of transaminases suggest liver involvement or, if treat-
ment has been initiated, drug toxicity. 
 CBC count 
 Leukopenia/leukocytosis may be present. 
 Leukemoid reactions may occur. 
Patients may have anemia. 
 Thrombocytopenia or, rarely, thrombocytosis may be present. 
 The erythrocyte sedimentation rate is elevated in approximately 50% 
of patients. 
 Cultures for mycobacteria (sputum, blood, urine, cerebral spinal fluid 
[CSF], and other body fluids, as available): Sensitivity testing is essential for all 
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positive isolates. Consider investigation for multidrug-resistant TB (MDR-TB) 
in all cases. 
 Coagulation studies: Measure the prothrombin time/activated partial 
thromboplastin time (PT/aPTT) prior to biopsy. 
 The tuberculin skin test with purified protein derivative (PPD) often 
yields negative results in patients with miliary TB. This may be explained by 
the large number of TB antigens throughout the body. 
 Nucleic acid probes 
Specificity for smear-negative and culture-negative specimens is lower 
than 100% (false-negative results). 
 False-positive TB cultures are of concern, and the rate is estimated to 
be approximately 5%. This may be due to laboratory contamination. 
 Polymerase chain reaction testing of the blood may yield positive re-
sults in most cases of HIV-related disseminated TB; the yield is low in non-
HIV miliary TB. 
 Mycobacterial blood cultures 
 Findings are positive in approximately 5% of patients who do not have 
HIV infection. 
 Findings are positive in many patients who have HIV infection. One 
study yielded an 85% positivity rate. 
Imaging Studies 
 Chest radiography 
 Findings are typical in 50% of cases. 
 A bright spotlight helps to reveal miliary nodules. 
Bilateral pleural effusions indicate dissemination versus localized and 
unilateral pleural TB. This may be a useful clinical clue. 
 Nodules characteristic of miliary TB may be better visualized on lat-
eral chest radiography (especially in the retrocardiac space). 
 Chest CT scanning 
 This has higher sensitivity and specificity than chest radiography in 
displaying well-defined randomly distributed nodules. High-resolution CT 
scanning with 1-mm cuts may be even better. 
 It is useful in the presence of suggestive and inconclusive chest radiog-
raphy findings. 
 Ultrasonography may reveal diffuse liver disease, hepatomegaly, 
splenomegaly, or para-aortic lymph nodes. 
 Head CT scanning with contrast and/or MRI of the brain 
 Use this to assess for suspected TB lesions. 
 Hydrocephalus or cerebral mass lesion (tuberculoma) may increase the 
risk of herniation if lumbar puncture is performed. 
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 Abdomen CT scanning may reveal para-aortic lymph nodes, hepa-
tosplenomegaly, or tuberculous abscess. 
 Echocardiography is the most sensitive test for pericardial effusion. 
Other Tests 
 Funduscopy: This may reveal retinal tubercles. 
 Electrocardiography 
o This test helps evaluate for pericardial effusion. 
o Right ventricular hypertrophy may indicate pulmonary hypertension 
prior to lung biopsy. 
 Contact investigation 
 Miliary TB in a child indicates recent transmission. Contact investiga-
tion could identify the source case and associated susceptibilities. 
 Contact investigation of child index cases should be conducted 
quickly. 
 Thoroughly evaluate household contacts by means of tuberculin skin 
testing and, if the test results are positive, chest radiography. 
Procedures: 
 Sputum induction has low sensitivity. Findings are smear-negative and 
culture-negative in 80% of patients because of hematogenous spread. 
 Fiberoptic bronchoscopy is the most effective procedure for obtaining 
 cultures (bronchoalveolar lavage). 
 The culture yield for transbronchial biopsies is 90%. 
 Lumbar puncture should be strongly considered, even with normal 
brain MRI findings. 
 Leukocytes: Approximately 65% of patients have WBC counts with 
100-500 mononuclear cells/μL. 
 Lymphocytic predominance (70%) 
 CSF lactic acid levels are mildly elevated. 
 Elevated protein levels (90%). 
 Low glucose levels (90%). 
 RBCs are common. 
 Acid-fast bacilli (≥40% with serial spinal taps). 
 Gastric lavage: This requires 3 prebreakfast samples, especially in 
children, with a yield of approximately 60%. 
 Nucleic acid amplification techniques may aid in the diagnosis, but 
negative findings do not rule out TB. 
 Bone marrow biopsy has no serious adverse effect. The yield is ap-
proximately 50%. 
 Liver biopsy: Liver bleeding is a serious and potentially life-
threatening complication estimated to occur in approximately 10% of cases. 
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 For abdominal involvement, laparoscopy is useful to obtain tissue and 
material for culture. 
Histologic Findings. Necrotizing granulomas are the hallmark of TB, 
and staining for acid-fast bacilli reveals rodlike structures in approximately 
80% of specimens. The disseminated nodules consist of central caseating ne-
crosis and peripheral epithelioid and fibrous tissue. Radiographically, the nod-
ules are not calcified. 
Staging. Miliary TB with meningeal involvement may require pro-
longed treatment (up to 12 mo). 
Medical Care. Early treatment of patients with suspected miliary tuber-
culosis (TB) decreases the likelihood of mortality and improves outcome. 
Surgical Care. Surgical treatment is rarely necessary. Occasionally, a 
ventriculoatrial shunt is indicated for hydrocephalus. 
Consultations  
 Pulmonary and critical care specialists 
 Infectious disease specialist 
Neurologist - Steroids for meningitis or paradoxically increasing 
 tuberculomas 
 TB expert 
 Health department notification 
 Appropriate infection control measures 
Diet. Adequate attention to nutrition is important. Many patients with 
miliary TB are debilitated by the disease, and malnutrition can contribute to a 
weakened immune system. 
Activity. Once the patient receives several weeks of effective therapy, 
experiences significant clinical improvement, and has negative sputum acid-fast 
bacillus smears, restrictions are minimal. However, one must be certain that the 
patient truly is no longer contagious. The absence of sputum positivity does not 
guarantee others protection against exposure. Directly observed therapy is op-
timal for assuring compliance and preventing relapse. 
Early empirical therapy for suspected miliary tuberculosis (TB) is pru-
dent. A delay of even 1-8 days contributes to a high mortality rate. 
Steroids are warranted for hypotension due to presumed adrenal insuffi-
ciency after an adrenocorticotropic hormone (ACTH) stimulation test. 
For susceptible organisms, the treatment period is 6-9 months. For men-
ingitis, it is 9-12 months. For miliary TB with meningeal involvement, daily 
medications for the entire length of therapy are recommended. 
Three basic rules apply in the prevention of entirely "doctor-made" re-
sistant TB, which cost more than $180,000 in the United States in 1991. First, 
rifampin is the drug of choice for treatment. In most cases, the treatment dura-
tion is at least 18 months without rifampin. Second, ethambutol (EMB) is used 
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to prevent rifampin resistance if the organism is resistant to isoniazid (INH). 
EMB can be discontinued as soon as the organism is found to be susceptible to 
rifampin and INH. Third, pyrazinamide is used for the first 2 months of treat-
ment to decrease the treatment duration from 9 months to 6 months if the or-
ganism is susceptible to rifampin and INH. 
For MDR-TB, use a minimum of 1 susceptible injectable and at least 3 
additional susceptible drugs to prevent the development of additional resis-
tance. Treat MDR-TB with the consultation of an expert in the care of TB. 
Intermittent-type therapies have not been established. If MDR-TB test 
results are pending, increasing the number of drugs is reasonable. For example, 
use 6 or 7 initial drugs, including an injectable. 
Antitubercular agents. Any regimen must contain multiple drugs to 
which TB is susceptible. In addition, drug therapy must be taken regularly and 
continued for a sufficient period. 
Miliary TB has a high number (load) of organisms; thus, the initial 
number of medications should be high. 
Rifampicin 
One of most important TB drugs. Used in combination with other anti-
tuberculous drugs in the treatment of all forms of TB. Without rifampin, the 
treatment duration is at least 18 mo. 
Inhibits DNA-dependent RNA polymerase activity in susceptible cells. Spe-
cifically, interacts with bacterial RNA polymerase but does not inhibit mammalian 
enzyme. Cross-resistance has been shown only with other rifamycins. 
Continue therapy for 6-9 mo or until at least 6 mo have elapsed from 
conversion to sputum culture negativity. 
Restart with different schedule if rifampin was discontinued because of 
adverse effects (eg, 20 min after a light meal, in divided doses). 
Adult. 600 mg/d IV if patient unable to tolerate PO or if reasons exist to 
suspect that PO medication will not achieve desired absorption 
Often can be changed to 600 mg PO 2 d/wk after the first 2 wk 
Pediatric. 10-20 mg/kg PO/IV; not to exceed 600 mg/d 
Izoniazid. Best combination of effectiveness, low cost, and minor adverse ef-
fects. First-line drug unless known resistance or another contraindication. Therapeutic 
regimens of <6 mo demonstrate unacceptably high relapse rate. 
Coadministration with pyridoxine recommended if peripheral neuropa-
thies develop secondary to INH therapy. Prophylactic doses of 6-50 mg/d of 
pyridoxine are recommended. 
Adult. 5 mg/kg/d (usually 300 mg/d) PO/IV and 10 mg/kg/d PO/IV in 1-
2 divided doses in patients with disseminated disease; not to exceed 300 mg/d 
In directly observed therapy, administer 15 mg/kg 2 times/wk PO/IV; not to 
exceed 900 mg/d. 
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Pediatric. 10-20 mg/kg/d PO/IV; not to exceed 300 mg/d. 
Pyrazine analog of nicotinamide that may be bacteriostatic or bacteri-
cidal against M tuberculosis, depending on concentration of drug attained at 
site of infection; mechanism of action is unknown. 
Administer for initial 2 mo of a 6-mo or longer treatment regimen for 
drug-susceptible cases. Treat drug-resistant cases with individualized regimens. 
Adult. 15-30 mg/kg/d PO; not to exceed 2 g/d. 
Alternatively, 1.5 g/d PO; increase to 2 g for body weight >75 kg, and 
decrease to 1 g for body weight <50 kg. 
Pediatric. Administer as in adults. 
Ethambutol 
Diffuses into actively growing mycobacterial cells, such as tubercle ba-
cilli. Impairs cell metabolism by inhibiting synthesis of one or more metabo-
lites, which, in turn, causes cell death. No cross-resistance demonstrated. 
Mycobacterial resistance is frequent with previous therapy. Use in these pa-
tients in combination with second-line drugs that have not been previously 
administered. 
Administer q24h until permanent bacteriological conversion and maximal 
clinical improvement is seen. Absorption is not significantly altered by food. 
Adult. No previous antituberculous therapy: 15 mg/kg/d (7 mg/lb/d) PO 
Previous antituberculous therapy: 25 mg/kg/d (11 mg/lb/d) PO 
Absorption not significantly altered by administration with food 
Pediatric. <12 years: Not recommended 
>12 years: Administer as in adults 
Streptomycin sulphate 
For treatment of susceptible mycobacterial infections. 
Use in combination with other antituberculous drugs (eg, INH, EMB, ri-
fampin). Total period of treatment for TB is a minimum of 1 y; however, indi-
cations for terminating streptomycin therapy may occur at any time. 
Recommended when less potentially hazardous therapeutic agents are 
ineffective or contraindicated. 
May be used in patients with severe liver dysfunction (transaminases 
>3- to 5-fold normal). 
Adult.  
2 times/wk dosing: 15 mg/kg/d IM; not to exceed 1 g/d. 
3 times/wk dosing: 25-30 mg/kg/d IM; not to exceed 1.5 g/d. 
Pediatric.  
2 times/wk dosing: 20-40 mg/kg/d IM; not to exceed 1 g/d. 
3 times/wk dosing: 25-30 mg/kg/d IM; not to exceed 1.5 g/d. 
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Levofloxacin 
Second-line drug with low risk of liver toxicity. Useful in TB in combi-
nation with rifampin and other antituberculosis agents. Other quinolones also 
may be useful, especially newer quinolones. 
Adult. 500 mg/d PO. 
Pediatric.  
<18 years: Not recommended, although it has been used in MDR-TB 
when options are limited 
>18 years: Administer as in adults 
 
Eosinophilic Granuloma 
Background. Eosinophilic granuloma, also known as pulmonary histio-
cytosis X (PHX) or pulmonary Langerhans cell histiocytosis X (PLCH), is an 
uncommon interstitial lung disease that is epidemiologically related to tobacco 
smoking. It chiefly affects young adults, primarily occurring in the third or 
fourth decades of life. 
Pathophysiology. Pulmonary Langerhans cell histiocytosis X 
(PLCH) is histologically characterized by parenchymal infiltration of the 
lungs by activated Langerhans cells. Langerhans cells are differentiated 
cells of the dendritic cell system and are closely related to the monocyte-
macrophage line. These antigen-presenting cells are normally found in the 
skin, reticuloendothelial system, heart, pleura, and lungs. They may be 
identified by immunohistochemical staining or by the presence of Birbeck 
granules via electron microscopy. 
PLCH is similar to pediatric histiocytic disorders (Letterer-Siwe disease 
and Hand-Sch ü ller-Christian disease). However, in contrast to pediatric 
histiocytoses, which involve multiple organs, PLCH usually manifests in a 
single organ — the lung. About 4-20% of patients with PLCH also have cystic 
lesions in the bones. Other organ systems are only rarely affected. 
The accumulation of Langerhans cells in the lungs is hypothesized to occur in 
response to exposure to cigarette smoke. Supporting this hypothesis is the finding that 
the initial histologic and radiographic findings are peribronchiolar. In addition, the 
disease is most prominent in the upper and middle lung zones, as seen in other smok-
ing-related lung diseases. The granulomatous infiltrates seen in PLCH are composed 
of Langerhans cells, eosinophils, lymphocytes, macrophages, plasma cells, and fibro-
blasts, which form nodules centered on the terminal and respiratory bronchioles, 
causing destruction of the airway walls. In late stages of the disease, fibrotic stellate 
scarring occurs, and end-stage PLCH is characterized by this scarring along with 
cystic spaces and honeycombing. 
History. Presentations of pulmonary Langerhans cell histiocytosis X 
(PLCH) are variable. Approximately 25% of patients are asymptomatic, and 
their disease is diagnosed after an evaluation of incidental findings on chest 
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radiographs. Others present with respiratory or constitutional symptoms. In 
order of decreasing frequency, common presenting symptoms are as follows: 
 Nonproductive cough (56-70%) 
 Dyspnea (40%) 
 Fatigue (30%) 
 Weight loss (20-30%) 
 Chest pain (21%) 
 Spontaneous pneumothorax, which may be recurrent, is a classic pres-
entation found in 10-20% of patients. 
 Fever (15%) 
 Cystic bone lesions (4-20%): These may be painful and may predis-
pose the patient to pathologic fracture. 
Physical. Patients with pulmonary Langerhans cell histiocytosis X 
(PLCH) present with nonspecific physical findings. Neither inspiratory rales 
(crackles) nor clubbing is common. Cor pulmonale may develop; therefore, the 
following related findings may be present: 
 Loud second heart sound with accentuated pulmonic component 
 Tricuspid regurgitation murmur 
 Right ventricular lift 
 Peripheral edema 
Causes 
No occupational causes or geographic predispositions are recognized for 
pulmonary Langerhans cell histiocytosis X (PLCH). People with PLCH, almost 
invariably, are cigarette smokers. Antigenic stimulation from 1 or more com-
ponents of tobacco smoke is likely responsible for the disease. Because only a 
few tobacco smokers develop the disease, other susceptibility factors, such as 
host genetics and environmental exposures, most likely play an important role 
in pathogenesis. Some reports in the literature also describe PLCH developing 
following radiation and/or chemotherapy for lymphoma. Additional investiga-
tion is needed to further our understanding of this disease process. 
 
Differential diagnoses 
 
Chronic Obstructive Pulmonary 
Disease Pulmonary Fibrosis, Idiopathic 
Cystic Fibrosis Pulmonary Fibrosis, Interstitial (Nonidiopathic) 
Emphysema Sarcoidosis 
Hypersensitivity Pneumonitis Wegener Granulomatosis 
Lymphangioleiomyomatosis  
Pneumocystis (carinii) jiroveci Pneu-
monia  
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Other Problems to Be Considered 
 Tuberous sclerosis 
 Lymphangioleiomyomatosis (LAM): Patients with pulmonary Langerhans 
cell histiocytosis X (PLCH) frequently present to medical attention with spontaneous 
pneumothoraces. Lymphangioleiomyomatosis is a disorder that exclusively affects 
young women and is characterized by cystic, emphysematous dilation of the terminal 
airways and shares this predisposition. It may be mistaken for PLCH on a chest radio-
graph or high-resolution CT (HRCT) scan of the chest. 
 Pulmonary histiocytic sarcoma 
Laboratory Studies 
 Results from routine laboratory testing in patients with pulmonary 
Langerhans cell histiocytosis X (PLCH) are nonspecific. 
 Peripheral eosinophilia is not observed. 
Imaging Studies 
 Chest radiographs in patients with pulmonary Langerhans cell histio-
cytosis X (PLCH) characteristically reveal bilateral, symmetric, ill-defined 
nodules and reticulonodular infiltrates. As the disease progresses, cystic lesions 
appear. An upper-zone predominance of radiographic findings with sparing of 
the costophrenic angles is typically observed. 
 Cystic lesions can be of various sizes and thin or thick walled. 
 Lung volume is normal or increased. 
 Honeycombing indicates advanced disease. 
 Bony lesions may occur on the ribs or any other site. 
 Hilar or mediastinal adenopathy is rare and should prompt the consid-
eration of sarcoidosis or malignancy. 
 Pleural effusion is uncommon. 
 HRCT of the chest may be virtually diagnostic in the appropriate 
 clinical setting. Pathognomonic findings include nodules and cysts, 
predominantly in the mid and upper lung zones, with sparing of the costo-
phrenic regions. The nodules may be cavitary and variable in size. Likewise, 
the cysts may be of various diameters and wall thicknesses. A broad differential 
diagnosis must be considered in the following situations: 
 If only nodules are present on HRCT, the findings are nonspecific, and a 
number of other granulomatous disorders cannot be excluded radiographically. 
 When cysts are an isolated finding, LAM must be considered as well. 
Unlike PLCH, LAM is usually uniformly distributed throughout the lungs. 
Sparing of the costophrenic angles supports a diagnosis of PLCH. 
 Emphysema is usually distinguishable, as walls do not surround the 
cystic spaces found in emphysema. However, extensive emphysema is some-
times difficult to differentiate from PLCH. 
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Other Tests 
 Pulmonary function testing in pulmonary Langerhans cell histiocytosis 
X (PLCH) patients can demonstrate all patterns of abnormality: Normal, re-
strictive, obstructive, or mixed. 
 Most patients have normal or near-normal total lung capacity with 
near-normal spirometry findings. 
 Gas exchange, as measured by the diffusing capacity for carbon mon-
oxide, is generally reduced. 
In rare cases, patients have reversible airflow limitation. 
 Gas exchange abnormalities may be present at rest. Although such ab-
normalities are most pronounced with exercise, most patients have a normal 
gradient of alveolar-arterial partial pressures. 
 Pulmonary exercise testing may demonstrate decreased exercise ca-
pacity with reduced oxygen utilization. Gas exchange, ventilatory, and pulmo-
nary vascular abnormalities may also be present. Therefore, exercise limitation 
is generally multifactorial. 
Procedures 
 Analysis of bronchioalveolar lavage (BAL) fluid is sometimes diag-
nostic in pulmonary Langerhans cell histiocytosis X (PLCH). 
 A greater than 5% increase in the number of Langerhans cells in BAL 
specimens is almost pathognomonic for PLCH. Although this finding is highly 
specific, it is not particularly sensitive. 
 Langerhans cells can be recognized by their characteristic staining for 
S-100 protein or peanut agglutination antigen. 
 These cells are CD1a-positive, and may also be identified by a specific 
monoclonal antibody (MT-1). 
 Although the disease is present in a patchy distribution, sometimes 
transbronchial biopsy may be diagnostic if sampling is done in a number of 
areas and sufficient tissue is obtained. 
 Immunostaining for Langerhans cells (CD1a) improves the sensitivity 
and specificity of the biopsy sample. 
The diagnostic yield is approximately 10-40%. 
 Open or thoracoscopic lung biopsy is the most sensitive and specific 
diagnostic modality, and is generally recognized as the criterion standard. 
 In addition to immunostaining, electron microscopy of tissue samples 
may be performed. 
 Langerhans cells demonstrate the characteristic intracytoplasmic 
Birbeck granules. These are found in all Langerhans cells, but they are 
present in increased numbers in the pathologic Langerhans cells found in 
the lesions of PLCH. 
 33 
Histologic Findings. The earliest lesions of pulmonary Langerhans cell 
histiocytosis X (PLCH) consist of Langerhans cells grouped around the small 
airways. These inflammatory lesions expand to form granulomatous nodules 
composed of Langerhans cells as well as eosinophils, macrophages, lympho-
cytes, plasma cells, and fibroblasts. 
In addition to looking for the typical morphologic features of Langerhans 
cells, immunostaining for S-100 and CD1a may also be useful. Electron microscopy 
helps in identifying Langerhans cells by demonstrating the presence of diagnostic 
pentilaminar cytoplasmic inclusion bodies, or Birbeck granules (x-bodies). 
Of note, eosinophils may not always be present. Therefore, the 
name eosinophilic granuloma, despite being a commonly accepted term, is 
a misnomer. 
Granulomas are centered on distal bronchioles. Evidence of pulmonary 
vascular involvement and respiratory bronchiolitis are often present, as well as 
infiltration and destruction of airway walls. As the disease progresses, cavita-
tion occurs as a result of this destruction. The nodule fibroses, eventually form-
ing a stellate scar. 
Hematoxylin-eosin staining is demonstrated in the image below: 
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Medical Care. Smoking cessation is the most important medical inter-
vention for pulmonary Langerhans cell histiocytosis X (PLCH). Smoking ces-
sation often stabilizes the disease and sometimes leads to regression. It is also 
helpful in preventing bronchogenic carcinoma. Largely because of the rarity of 
PLCH, well-designed, prospective, randomized data regarding therapy are 
lacking. Treatment considerations are as follows: 
 The use of corticosteroids is controversial. Corticosteroids may be 
considered in patients with a persistence of clinically significant pulmonary or 
constitutional symptoms or those with documented progression of disease. 
Corticosteroid therapy is not indicated in patients with normal lung function. 
Recommendations for the use of corticosteroids are based largely on retrospec-
tive data and expert opinion. 
 Investigational therapies include interleukin-2 (IL-2) and anti–tumor 
necrosis factor-alpha (anti–TNF-alpha). Both agents have been reported to 
improve outcomes in pediatric disseminated histiocytosis. This finding may 
lead to the investigation of their use in adult PLCH. 
 Useful adjunctive therapies include the following: 
 Supplemental oxygen therapy for those with clinically significant hy-
poxemia (SaO2 <89% or PaO2<55 mmHg) at rest or with exertion 
 Aggressive treatment for pulmonary infections with prompt initiation 
of antibiotic therapy 
 Bronchodilator therapy in the presence of an obstructive ventilatory defect 
Surgical Care. Lung transplantation is an option for select patients with 
advanced disease. Recurrence of pulmonary Langerhans cell histiocytosis X 
(PLCH) has been reported in the transplanted lung. 
Consultations. Refer patients with suspected pulmonary Langerhans cell 
histiocytosis X (PLCH) to a pulmonary disease specialist. 
Activity. Exercise and pulmonary rehabilitation are encouraged in 
pulmonary Langerhans cell histiocytosis X (PLCH). These activities may 
improve the patient's functional status, even if they have no effect on 
disease progression. 
Medication. The mainstays of treatment for pulmonary Langerhans cell 
histiocytosis X (PLCH) are smoking cessation and supportive therapy. The use 
of corticosteroids in the treatment of PLCH is controversial. Their efficacy has 
not been proven in well-designed, prospective, randomized, controlled trials. 
Some experts recommend a trial of corticosteroids for those patients with per-
sistent symptomatic disease or evidence of progression. 
Corticosteroids. These agents have anti-inflammatory properties and 
cause profound and varied metabolic effects. Corticosteroids modify the body's 
immune response to diverse stimuli. 
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Prednisolone 
Used as immunosuppressant to treat autoimmune disorders. By revers-
ing increased capillary permeability and suppressing activity of polymorphonu-
clear cells, may decrease inflammation. Oral corticosteroid with relatively lim-
ited mineralocorticoid activity. Best prescribed in consultation with pulmonary 
disease specialist. 
Adult 
0.5-1.0 mg/kg/d PO initially, followed by 6- to 12-mo taper 
Pediatric 
Not established 
 
 Literature 
o Goodman & Gilman’s  The Pharmacological Basis of Therapeutics / 
Laurence L. Brunton, Keith L. Parker, Donald K. Blumenthal, Iain L.O. Buxton 
/ 11th edition / 2007  
o Basic & Clinical Pharmacology / Bertram G. Katzung / 10th edition / 
2006 
o Katzung & Trevor's Pharmacology: Examination & Board Review / 
Trevor AJ, Katzung BG, & Masters SB /  7th edition /  2005 
o USMLE Road Map: Pharmacology / Katzung BG, Trevor AJ / 2nd 
edition / 2006. 
o Current Medical diagnosis and treatment/ Edited by Lawrence M Tier-
ney/ 2010 
o Harrison’s principles if internal medicine-17th edition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 36 
Навчальне видання 
 
 
Модуль 3. Внутрішні хвороби.  
Змістовний модуль №4. 
Тема 3. Ведення хворих  
з затемненням в легенях 
 
Методичні вказівки  
для студентів та лікарів-інтернів 
 
 
Упорядники 
 
Бабак Олег Якович    
Фадєєнко Галина Дмитрівна 
Біловол Олександр Миколайович 
Школьник Віра Владиславівна 
Шапошнікова Юлия Миколаївна 
Немцова Валерія Данилівна 
Железнякова Наталя Мерабівна 
 
Відповідальний за випуск  Бабак О.Я. 
 
 
Комп’ютерний набір  
Ю.М. Шапошнікова 
 
 
 
 
План 2012, поз. 27. 
Підп. до друку 12.06.2012. Формат А5. Папір типогр. Різографія. 
Умов. друк. арк. 2,25. Тираж 150 прим. Зам. № 12-2929. 
_______________________________________________________________________ 
Редакцийно-видавничий відділ 
ХНМУ, пр. Ленина, 4, г. Харків, 61022 
izdat@knmu.kharkov.ua 
 
Свіидоцтво про внесення суб’екта видавничої справи до Державного реєстру видавництв,  
виготивників і розповсюджувачів видавничої продукції серії ДК № 3242 від 18.07.2008 р. 
 37 
Module 3. Internal medicine.  
Contents module № 4. 
Theme 3. Management of patients  
with infiltrative pulmonary darkening 
 
Guidelines for students and interns 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Модуль 3. Внутрішні хвороби.  
Змістовний модуль  №4. 
Тема 3. Ведення хворих  
з затемненням в легенях 
 
Методичні вказівки  
для студентів та лікарів-інтернів 
